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Laminins are heterotrimeric basement membrane (BM) glycopro-
teins consisting of α, β, and γ chains. In mammals there are 5 α, 
4 β, and 3 γ chains that assemble to form at least 15 heterotrimers 
(1). Laminins provide the basic scaffold for assembly of other BM 
components, including type IV collagen, nidogen/entactin, and 
sulfated proteoglycans (2). BMs are the thin sheets of extracellular 
matrix adjacent to many cell types, including most epithelia and 
endothelia. Their importance extends beyond merely providing 
mechanical support for cells; BMs are critical for cell proliferation, 
differentiation, survival, and function, as has been clearly shown in 
human diseases or animal models with BM abnormalities (1, 3).
The kidney glomerular BM (GBM) is an unusually thick BM 
formed via fusion of distinct BMs assembled by glomerular epi-
thelial cells (podocytes) and glomerular endothelial cells (4). The 
GBM is functionally unique; it must facilitate constant fluid 
flow across the glomerular filtration barrier (GFB) — consisting 
of endothelium, GBM, and podocyte — while tolerating hemo-
dynamic stresses and providing support for glomerular cells. 
The composition of the GBM is also specialized, as it is the only 
nephron-associated BM in the kidney whose laminin composi-
tion is exclusively laminin α5β2γ1, referred to as LM-521 in the 
new nomenclature (3, 5).
Whereas the α5 chain, as part of LM-511 (α5β1γ1) and LM-
521, is required for GBM integrity and glomerular vascular-
ization (6), the β2 chain is dispensable for glomerulogenesis. 
Laminin β2–null (Lamb2–/–) mice are born alive overtly indistin-
guishable from normal littermates (7, 8). GBM ultrastructure 
appears essentially normal, because LM-511, normally found 
in immature GBM, compensates structurally for the missing 
LM-521 in mature GBM (8). Lamb2–/– mice develop severe neu-
romuscular defects and nephrotic syndrome with progressive 
foot process (FP) effacement. Mutant mice fail to thrive; they 
stop gaining weight at P7 and die at approximately P21 due 
primarily to the neuromuscular defects (9). The mouse Lamb2–/– 
phenotype shows similarities to Pierson syndrome, a recently 
described human disease resulting from LAMB2 mutations and 
characterized by ocular abnormalities, psychomotor defects, and 
congenital nephrotic syndrome (10).
The cardinal feature of nephrotic syndrome is severe protein-
uria resulting from increased flux of albumin and other plasma 
proteins across the GFB. The GBM’s role in glomerular permse-
lectivity, if any, is not clear, and it is now considered secondary to 
that of the podocyte slit diaphragm (SD) (11, 12). Nevertheless, 
proteinuria can result from either primary podocyte or primary 
GBM defects, so how a GBM compositional or structural defect 
might cause proteinuria is still debated. Some investigators have 
suggested podocyte detachment from the GBM as a possible expla-
nation (13), and this was supported in some kidney injury models 
by the presence of viable podocytes in urine (14). However, in the 
absence of an acute, severe injury, it is rare to find denuded GBM. 
Another possibility is that abnormal matrix components signal 
anomalously via podocyte cell surface receptors and disrupt podo-
cyte homeostasis, but this has not been addressed in vivo. The last 
theory is that the GBM is a major factor in determining glomeru-
lar permselectivity by acting as a modified gel through which mac-
romolecules such as albumin pass primarily by diffusion, indepen-
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dent of fluid flow (the gel permeation/diffusion hypothesis; ref. 
15). In this model, an increased protein concentration in the glo-
merular ultrafiltrate can result from either of 2 mechanisms: (a) 
an alteration in the composition of the GBM, as occurs in Pierson 
syndrome and Alport syndrome (16, 17); or (b) a reduction in the 
rate of fluid flow across the GFB, as is proposed to occur in cases 
of FP effacement due to reduced filtration slit frequency, without 
change in the rate of protein diffusion (15).
Tubules also play an important role in proteinuria, as the con-
centration of protein in the final urine is determined not only by 
the GFB but also by tubular reabsorption of filtered protein. Previ-
ous work using isolated proximal tubules suggests that albumin 
uptake is biphasic; there is a high-affinity/low-capacity pathway 
that is saturable at physiologic albumin concentrations and a low-
affinity/high-capacity pathway associated with bulk fluid uptake 
(18). This underscores the importance of albumin concentration 
in the glomerular filtrate rather than the absolute amount, a con-
cept invoked by the gel permeation/diffusion hypothesis (15).
Here we investigated the compositional, structural, and func-
tional changes in the GBM of Lamb2–/– mice and the pathophysi-
ological consequences. This study was aided by the development 
of separate transgene-mediated rescues of the neuromuscular and 
glomerular components of the failure-to-thrive phenotype (9). 
Lamb2–/– mice carrying a muscle-specific β2 transgene gain weight 
normally and only exhibit the glomerular defect. Thus, our analy-
ses of the GFB in older nephrotic mice are not subject to poten-
tially confounding extrarenal defects. Using the electron-dense 
tracer ferritin, we were able to test the gel permeation hypothesis 
and identify mechanistic differences in permselectivity defects 
between the Lamb2–/– (GBM defect) and CD2-associated protein–
null (Cd2ap–/–) (podocyte defect) models of nephrotic syndrome. 
Our results show that the GBM has intrinsic and mutable barrier 
properties in response to ferritin in vivo, independent of FP archi-
tecture, and we conclude that the same is likely true for albumin.
Results
Lamb2–/– mice exhibit a failure-to-thrive phenotype with severe 
neuromuscular weakness and congenital nephrotic syndrome 
(7, 8), features consistent with human Pierson syndrome (10). In 
order to study these defects independently, we generated trans-
genic mice expressing rat laminin β2 either in muscle (using the 
muscle creatine kinase promoter; MCK-B2 transgene) or in podo-
cytes (using the nephrin promoter; NEPH-B2 transgene). When 
bred onto the Lamb2–/– background, MCK-B2 rescues the neu-
romuscular junction defects, and NEPH-B2 prevents nephrotic 
syndrome (9). Although rescue of muscle has no effect on pro-
teinuria, Lamb2–/–MCK-B2 mice are overall much healthier than 
Lamb2–/– mice. Nevertheless, Lamb2–/–MCK-B2 mice die at 1 
month of age from nephrotic syndrome (9) with elevated blood 
urea nitrogen levels (data not shown). Here, we took advantage of 
the improved health and weight gain of Lamb2–/–MCK-B2 mice to 
study the isolated GFB defect in more detail.
GBM composition and podocyte laminin receptors. During glomerular 
maturation, a developmental shift in the laminin components of 
the GBM occurs, from LM-111 to LM-511 to LM-521 (19). In the 
absence of laminin β2, laminin β1 persists in the GBM (8). Simi-
larly, in Alport syndrome there is reexpression of fetal laminins α1 
and β1 (16, 20), suggesting the possible existence of a compensa-
tory response to abnormal GBM. We further investigated GBM 
laminin content in Lamb2–/– mice. Laminin α5 was present in the 
GBM regardless of whether laminin β2 was present, but levels were 
reduced in Lamb2–/– GBM (Figure 1, A–D). In normal kidneys the 
GBM lacked laminin α1 and α2 and LM-332 (Figure 1, E, G, and I), 
whereas Lamb2–/– GBM exhibited linear staining for all these lami-
nins (Figure 1, F, H, and J). Together with the presence of protein-
uria, these results suggest that ectopic laminins are not sufficient to 
restore GFB function, and their deposition in the GBM may even be 
pathogenic, as proposed for ectopic laminins in Alport syndrome 
Figure 1
Immunofluorescence detection of glomerular laminins. Frozen sections 
of normal (left) and Lamb2–/– (right) kidneys were stained for laminin 
β2 (Lamβ2; A and B), α5 (C and D), α1 (E and F), α2 (G and H), and 
α3β3γ2 (LM-332; I and J). Normal GBM contains laminin β2 and α5 
(and γ1; data not shown); laminin α5 was decreased in Lamb2–/– GBM. 
Normal glomeruli exhibit variable mesangial staining for laminin α1 and 
α2 but not LM-332; however, all were detected ectopically in Lamb2–/– 
GBM. Original magnification, ×600.
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(16, 17, 20). We also investigated podocyte laminin receptor expres-
sion, which is represented primarily by integrin α3β1. Antibody 
staining for integrin α3 revealed normal distribution and intensity 
early in the disease process (P7; Figure 2, A and B). In contrast, in 
older mice (2–4 weeks), there were subtle but clear differences in 
intensity and distribution. Integrin α3 staining was less intense 
and lost its typical linear localization (Figure 2, C and D), in paral-
lel to the progressive nephrotic syndrome and FP effacement. In 
contrast, no changes were detected in integrin α6, integrin α8, or 
α-dystroglycan localization or expression (data not shown).
Expression of SD components. Currently, the most favored views 
of the GFB propose the podocyte SD as the predominant deter-
minant, with proteinuria and nephrotic syndrome ensuing upon 
loss or alteration of SD components or associated proteins (21, 
22). We therefore considered the possibility that alterations in the 
Lamb2–/– GBM caused proteinuria indirectly by altering expression 
or localization of SD components. However, despite congenital 
albuminuria in Lamb2–/– mice (Figure 3A), nephrin (Figure 2, E 
and F) and podocin (Figure 2, I and J) showed normal distribu-
tion and intensity until P14. It was not until after approximately 
P21 that we were able to detect significant changes in nephrin and 
podocin levels and distribution (Figure 2, G, H, K, and L), which 
were comparable to the changes in integrin α3 and likely reflect-
ed the widespread FP effacement (9). In addition, we previously 
reported that CD2AP exhibits an abnormal granular distribution 
in P21 Lamb2–/– podocytes, whereas distribution at P9 was normal 
(23). These observations suggest that changes in integrin and SD 
components are unlikely to be the primary cause of proteinuria, 
but they rather represent secondary changes related to progression 
of disease caused by the primary GBM defect.
Glomerular features. To further investigate the temporal rela-
tionship between podocyte FP effacement and proteinuria, we 
followed these events chronologically. Increased urinary albu-
min excretion was detected by SDS-PAGE in Lamb2–/– mice as 
early as P2 (Figure 3, A and D). Kidneys from the same animals 
were viewed using scanning electron microscopy (SEM). Despite 
increased albumin excretion, there was no detectable FP efface-
ment (Figure 3, B, C, E, and F). The most distinctive change was 
mild podocyte cell body villous transformation (Figure 3 and 
Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI28414DS1), which was detected 
previously in experimental nephrotic diseases (24). Transmission 
electron microscopy (TEM) confirmed the presence of normal-
appearing SDs and the absence of FP effacement at early ages 
(Supplemental Figure 2). Segmental podocyte FP effacement was 
evident at approximately P10 (Figure 3, H and I), whereas the 
GBM itself generally appeared normal even near the time of death 
(9), except for occasional, mild, segmental irregularities.
Negative charge characteristics. Although laminins are not consid-
ered to be highly charged, they do provide the scaffold for incor-
poration of BM components that impart anionic charge, such as 
the sulfated proteoglycans perlecan and agrin. GBM anionic sites 
revealed by polyethylenimine labeling are normally distributed at 
regular intervals juxtaposed to podocytes and endothelial cells, 
but they are sparse in the middle of the GBM (the lamina densa) 
(25). Charge density on the podocyte aspect is relatively constant 
throughout life, but charges at the endothelial aspect decrease 
with age, and in mice they reach a stable number and distribution 
at 3–4 weeks. Previously it was shown that negative charge distri-
bution and number correlated well with GBM abnormalities in 
diabetic rats and was disorganized in proteinuric diseases (26). In 
newborn Lamb2–/– mice, the number of anionic sites at the podo-
Figure 2
Immunofluorescence detection of podocyte proteins. Frozen sec-
tions of normal (left) and Lamb2–/– (right) kidneys at P7 and P28 were 
stained for integrin α3 (Intα3; A–D), nephrin (E–H), and podocin (I–L). 
There were no detectable changes in intensity or distribution of these 
proteins in young mice. However, with age and disease progression, 
there was a reduction in intensity; all 3 seemed to lose their normal lin-
ear distribution and showed a more diffuse granular pattern. This likely 
reflects the retraction of FPs and reduced SD density. Magnification, 
P7, ×200; P28, ×600.
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cyte aspect of the GBM was mildly reduced (Figure 4A), and in 
general they were less regularly distributed compared with those in 
control or non-nephrotic Lamb2–/–NEPH-B2 mice. There was also 
a slight trend toward more anionic sites in the Lamb2–/– lamina 
densa (Figure 4A). After P14 there was a great increase in the num-
ber of anionic sites in the lamina densa, and the mild reduction 
at the podocyte aspect persisted with age (Figure 4, B–D). Besides 
these quantitative differences, Lamb2–/– charged sites tended to be 
smaller and irregularly spaced as compared with those in litter-
mate controls, especially in older mice. Thus, the lack of laminin 
β2 results in disorganization of anionic charges. In the absence of 
specific methods for probing GBM organization, we propose that 
these data reflect an overall disorganization of GBM architecture.
Ferritin permeability. To test the consequences of altered GBM 
composition and organization in Lamb2–/– mice, we used native 
ferritin as a tracer. Ferritin is a large, 480-kDa protein with an 
iron core containing up to 2,500 iron atoms, making it electron 
dense. It has been used since the early 1960s to study glomeru-
lar permselectivity (27). Ferritin was injected intravenously into 
control/Lamb2–/– littermate pairs at P11–P23 and visualized by 
TEM. There was a substantial increase in the number of ferritin 
particles in Lamb2–/– versus control GBM as early as 5 minutes 
after injection (data not shown), and this persisted at later time 
points. Multiple experiments comparing littermates at 1 (Fig-
ure 5A and Supplemental Figure 3) and 2 hours (Figure 5, B–D, 
Figure 3
Relationship between proteinuria and FP effacement in Lamb2–/– 
glomeruli. (A, D, and G) Equal volumes of urine from normal (left 
lanes) and Lamb2–/– (right lanes) littermates at P2, P5, and P10 
(respectively) were analyzed by SDS-PAGE. Corresponding kidneys 
from normal (B, E, and H) and Lamb2–/– (C, F, and I) mice were ana-
lyzed by SEM. At P2 (B and C) and P5 (E and F), there were no signs 
of FP effacement, whereas areas of effacement were evident at P10 
(H and I). Scale bar in I: 3 μm.
Figure 4
GBM anionic charge distribution. Anionic sites were localized in 
normal and Lamb2–/– glomeruli (as indicated) at birth (A) and after 
2 weeks of age (B–D) using polyethylenimine. Anionic sites were 
counted and expressed as the number of sites/micrometer of GBM 
length in either the lamina densa (LD; middle of the GBM) or the 
lamina rara externa (LRE; podocyte aspect). There was a slight but 
consistent reduction in the total number of LRE anionic sites in the 
Lamb2–/– GBM, but an increase in the number of LD anionic sites at 
later ages, consistent with GBM disorganization. Data shown in A 
and B are mean ± SD. Scale bars: 125 nm.
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and Supplemental Figure 4) after injection consistently showed 
increased ferritin levels in the mutant GBM. The difference was 
even greater for subepithelial ferritin particles (Figure 5, A and B, 
and Supplemental Figures 3 and 4). Importantly, the presence or 
absence of FP effacement did not significantly affect GBM ferritin 
permeability. Furthermore, ferritin permeability in non-nephrotic 
Lamb2–/– mice carrying the NEPH-B2 transgene was normal (Fig-
ure 5, A and B), providing additional evidence that expression of 
laminin β2 solely by podocytes is sufficient for a normal GFB. 
Although there was some variability among experiments, this did 
not alter the overall conclusion; total ferritin numbers were 1.7- 
to 5.2-fold higher in Lamb2–/– GBM, and the subepithelial ferritin 
was 1.7- to 13.7-fold higher. Thus, the primary GBM defect 
increased the permeability of the GBM to ferritin independent of 
detectable podocyte defects.
To assay ferritin permeability in mice with proteinuria due to a 
primary podocyte defect, we used Cd2ap–/– mice. These mutants 
develop proteinuria during the first 10 days of life and eventually 
die with nephrotic syndrome and extensive glomerular fibrosis at 
7–13 weeks, but GBM composition appears normal (28, 29). GBM 
ferritin distribution was surprisingly different from that observed 
in Lamb2–/– mice: (a) the total number of GBM ferritin particles was 
unchanged from control; and (b) there was a trend toward fewer 
(~70% of control) subepithelial par-
ticles in Cd2ap–/– GBM, even in areas 
with extensive FP effacement (Fig-
ure 6 and Supplemental Figures 5 
and 6). Together, these ferritin stud-
ies in 2 distinct models of nephrotic 
syndrome reveal a clear difference 
in intrinsic GBM permeability that 
depends upon and is consistent with 
the nature of the primary defect.
Discussion
Nephrotic syndrome describes a 
heterogeneous group of kidney 
diseases characterized by increased 
urinary protein (especially albu-
min), edema, hypoalbuminemia, 
hyperlipidemia, and lipiduria. 
Although the definition is clear, 
and disruption of the GFB is a 
shared feature, the etiology and 
rate of progression to renal fail-
ure varies. Extensive studies over 
the last 50 years have attempted 
to define the role of each of the 
3 layers that constitute the GFB 
in mediating permselectivity, yet 
controversy still exists. Initially the 
GBM was viewed as the predomi-
nant factor, but recent investiga-
tions have revealed strong, direct 
links between proteinuric disorders 
of both genetic and idiopathic ori-
gins to podocytes and the SD (21, 
22, 30, 31).
The availability of animal mod-
els provides powerful tools for 
attempting to distinguish the role of the GBM and SD. Here 
we have used Lamb2–/– and Cd2ap–/– mice, 2 distinct models of 
nephrotic syndrome, to better understand the nature of the GFB. 
By both following the progression of proteinuria with respect to 
the timing of podocyte FP effacement and quantitating the entry 
of an electron-dense tracer molecule into the GFB, we have found 
strong evidence that the GBM serves as a major barrier to plasma 
protein that acts independently of the overlying podocyte. Despite 
ferritin’s large size compared with albumin (480 versus 67 kDa), 
previous localization of albumin in normal rat glomeruli by Ryan 
and Karnovsky (32) showed a pattern with striking similarity to 
that of ferritin in our normal mice.
Proteinuria in Lamb2–/– mice stems from a primary GBM defect. 
Laminin β2 is part of LM-521, the predominant laminin in mature 
GBM. In the absence of laminin β2, and despite compensation by 
other laminins, the GBM is abnormally organized, as shown by 
aberrant localization of anionic sites. The abnormal organization 
could arise in part from the deposition of multiple ectopic lami-
nins (LM-511, -111, -211, and -332) that are not normally found in 
the GBM but whose presence is expected to change the usual gel 
properties and overall porosity of the GBM (26). This could lead 
to the observed increased permeability and exposure of podocytes 
to atypical hemodynamic forces.
Figure 5
Increased GBM permeability to ferritin in Lamb2–/– mice. Ferritin was detected in the GBM either 1 (A) or 
2 (B) hour after a single intravenous injection into control/mutant littermate pairs, at the indicated ages. 
Ferritin particles were counted in the total surface area of the GBM (expressed as number of ferritin 
particles/10,000 nm2) or only at the subepithelial (podocyte) aspect (expressed as number of ferritin 
particles/μm of GBM length). There was an increase in total and in subepithelial ferritin at 1 hour in all 
Lamb2–/– mice compared with control or non-nephrotic, rescued Lamb2–/– mice carrying the NEPH-B2 
transgene (Res). The increase was more remarkable after 2 hours in the older mice. (C–F) Represen-
tative electron micrographs showing ferritin particles in the GBM of normal (C and D) and Lamb2–/– (E 
and F) mice at P11. Note the increased ferritin in the mutant GBM despite the normal FP architecture. 
D and F are higher magnifications of C and E, respectively. Scale bars: 125 nm.
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We also examined podocyte architecture early during disease 
course and defined its relationship to proteinuria. During the 
first week of life, proteinuric Lamb2–/– mice had apparently normal 
FPs and SDs, and it was not until the second week that there was 
gradual FP effacement and loss of SDs. Thus, increased urinary 
protein clearly preceded detectable podocyte FP and SD changes. 
Proteinuria in the absence of widespread FP effacement indicates 
that the SD, which appears intact in young Lamb2–/– mice, is not 
a wholly effective barrier to albumin, a conclusion also reached 
in rat studies (33). However, here we cannot rule out the possibil-
ity that the observed SDs are defective. We note that we are not 
the first to report the existence of proteinuria in the absence of 
FP effacement; it has also been observed in preeclampsia, in other 
animal models, and in sporadic human cases (34–38).
In contrast to our findings in Lamb2–/– mice, entry of ferritin into 
the GBM was near normal in heavily proteinuric Cd2ap–/– mice, 
which have a primary podocyte defect and a compositionally nor-
mal GBM (28, 29). This shows that not all nephrotic mice exhibit 
GBM ferritin permeability changes, and it provides further sup-
port for the notion that the GBM is the primary sieve and acts as a 
modified gel, in accord with the gel permeation/diffusion hypoth-
esis (15). This hypothesis introduced the idea that the mechanism 
of proteinuria varies depending on the site of the primary defect 
(GBM or podocyte). The hypothesis predicts that only slightly fewer 
macromolecules will cross the normal GBM in the presence of FP 
effacement, but the accompanying reduced hydraulic permeability 
(12, 39) of the GFB (i.e., reduced single-nephron GFR) will lead to 
a decreased dilution factor and a greatly increased concentration 
of macromolecules in the glomerular filtrate. This is in contrast 
to an abnormal GBM, where there is a simple increased flux of 
macromolecules. In both cases, the proximal tubule’s protein reab-
sorption machinery would then be unable to 
handle this increased concentration, resulting 
in proteinuria (15).
So what causes the eventual FP effacement 
in Lamb2–/– mice? In vitro studies suggest 
that albumin and IgG at plasma concentra-
tions stimulate changes in the podocyte cyto-
skeleton that could cause or be indicative of 
podocyte damage (40). Although in culture 
the exposure affects the apical surface, mul-
tiple observations have suggested that podo-
cytes can exhibit high endocytic activity at 
the basolateral surface in vivo, especially 
in nephrotic conditions (27, 41–44). Thus, 
there may be a tremendous advantage to sheltering podocytes 
from high plasma protein concentrations, which in turn under-
scores the central importance of the GBM in serving as the major 
component of the GFB.
One important outcome of these studies is that we have been able 
to show in situ that the GFB is differentially affected in 2 geneti-
cally defined proteinuric diseases, reinforcing the notion that 
high-level proteinuria can reflect different mechanistic paths. It is 
also notable that nephrin, podocin, CD2AP, and integrin α3 were 
localized normally until the second week despite the proteinuria 
in Lamb2–/– mice, consistent with normal podocyte architecture, 
but eventually their intensity and distribution changed markedly. 
Given that these abnormalities are far removed from the primary 
insult that causes proteinuria (i.e., lack of laminin β2), caution 
should be used in drawing conclusions from similar analysis of 
human biopsy samples, as they are invariably taken late during 
the course of disease.
Methods
Animal models. Lamb2–/– mice and podocyte- and muscle-specific transgenic 
rescue of Lamb2–/– phenotypes have been described (7–9), as have Cd2ap–/– 
mice (28). Lamb2–/–MCK-B2 (muscle-rescued) mice were used as mutants 
for most experiments; in a few cases, Lamb2–/– mice younger than P12 
without the transgene were used. For simplicity, all mutants are designat-
ed Lamb2–/–, indicating glomerular genotype. Control/mutant pairs were 
taken from the same litter. All procedures and experiments were approved 
by the Washington University Animal Studies Committee.
Urinalysis. Equal volumes of urine (15 μl) were analyzed on precast 4–20% 
SDS polyacrylamide gels	(Invitrogen), which were stained with Coomassie 
blue. For quantitation, protein and creatinine concentrations were mea-
sured with a COBAS MIRA plus analyzer (Roche Diagnostics).
Figure 6
Normal GBM permeability to ferritin in Cd2ap–/– 
mice. Ferritin injections were performed in 
Cd2ap–/– and control littermate mice. (A and B) 
Total numbers of ferritin particles in the GBM 
at 1 and 2 hours after injection were similar in 
nephrotic Cd2ap–/– mice and their normal litter-
mates at P21. However, subepithelial ferritin par-
ticle numbers were lower in the mutant, despite 
the albuminuria. (C–F) Representative electron 
micrographs showing ferritin particles in the 
GBM of P21 normal (C and D) and Cd2ap–/– (E 
and F) mice. D and F are higher magnifications 
of C and E, respectively. Scale bars: 125 nm.
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Light and electron microscopy. Kidneys were fixed in 10% buffered formalin, 
embedded in paraffin, sectioned, and stained with H&E and PAS by stan-
dard methods. For TEM, tissues were fixed, embedded in plastic, sectioned, 
and stained as previously described (8). For SEM, small pieces (approxi-
mately 2-mm cubes) of kidney cortex were fixed in 3% phosphate-buffered 
glutaraldehyde and postfixed in 1% phosphate-buffered osmium tetroxide. 
Samples were dehydrated in graded ethanols and critical-point dried in 
carbon dioxide. The cubes were then cracked into pieces by stressing with 
the edge of a razor blade and mounted with glue onto stubs. The surface 
was sputter-coated using gold/palladium and visualized by SEM.
Antibodies and immunofluorescence. Rabbit anti-mouse laminin α5 serum 
was described previously (45). Rat anti-mouse laminin α2 mAb 4H8-2 was 
purchased from ALExIS Biochemicals (Axxora). Other primary antibodies 
were gifts from generous colleagues: rabbit anti-mouse laminin β2 (46) 
from Takako Sasaki and Rupert Timpl, Max Planck Institute for Bio-
chemistry, Martinsried, Germany; rat anti-mouse laminin α1 mAb 8B3 
(47) from Dale Abrahamson, University of Kansas Medical Center, Kan-
sas City, Kansas, USA; rabbit anti-human laminin-332 (α3β3γ2) (48) from 
Peter Marinkovich, Stanford University, Stanford, California, USA; rabbit 
anti-chick integrin α3 (49) from Mike Dipersio, Albany Medical College, 
Albany, New York, USA; rabbit anti-mouse nephrin (50) from Lawrence 
Holzman, University of Michigan, Ann Arbor, Michigan, USA; rabbit 
anti-human podocin (51) from Corinne Antignac, Necker Hospital, Paris. 
Alexa 488- and Cy3-conjugated secondary antibodies were purchased from 
Invitrogen and Chemicon International, respectively. Immunofluorescence 
analysis was performed as previously described (9).
Negative charge detection. Using a method modified from ref. 52, small 
kidney cortex pieces were incubated in 0.5% polyethylenimine (1.8 kDa; 
Sigma-Aldrich), pH 7.3, for 30 minutes on ice, washed, and fixed in 2.5% 
glutaraldehyde containing 2% phosphotungstic acid for 1 hour on ice. 
After washing, tissues were postfixed in 1% osmium tetroxide for 2 hours 
at 4°C. Samples were then dehydrated and embedded in plastic. Ultrathin 
sections were viewed by TEM without staining. Three to 4 glomeruli were 
visualized for each condition, with a minimum of 8 individual loops pho-
tographed. Ten mice at P0 (4 mutant and 6 control) and 9 in the older 
group (4 mutant and 5 control) were assayed. To reveal abnormalities in 
the distribution of GBM anionic sites, the numbers of polyethylenimine-
positive sites in the lamina densa and lamina rara externa were determined 
using high-resolution images. GBM length was calculated using SPOT 
4.0.1 software (Diagnostic Instruments). Data are mean ± SD.
Ferritin permselectivity. Using methods modified from Farquhar (27), horse 
spleen ferritin (50 mg/ml in 0.9% NaCl) was administered via tail vein injec-
tion at 10 μl/g body weight. After various times (5 minutes to 2 hours), 
kidneys were fixed in situ by injecting fixative (4% paraformaldehyde, 4% 
glutaraldehyde) beneath the capsule. After 5 minutes kidneys were cut into 
small pieces that were further fixed in 1% paraformaldehyde, 1% glutaralde-
hyde overnight and postfixed in 1.5% potassium ferrocyanide, 1% osmium 
tetroxide. Specimens were dehydrated, embedded in plastic, sectioned, and 
visualized by TEM unstained. To quantify GBM permeability, electron-dense 
ferritin particles in the GBM were counted using high-resolution images. 
Total GBM surface area and length were calculated using SPOT software 
(Diagnostic Instruments). Ferritin numbers were expressed as total/10,000 
nm2 of GBM surface area and subepithelial ferritin/micrometer GBM length. 
Subepithelial refers to the distal third of the GBM, nearest the FPs.
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